Urinary Cell-Cycle Arrest Biomarkers as Early Predictors of Acute Kidney Injury After Ventricular Assist Device Implantation or Cardiac Transplantation

Alam, Amit; Jamil, Aayla K.; Zyl, Johanna Van; Medel-Martinez, Horacio; Wasek, Brandi; Felius, Joost; Lima, Brian; Hall, Shelley; Joseph, Susan

doi:10.1053/j.jvca.2021.10.013

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 mL (kg h) −1 for 6 hours to define AKI stage 1. [57,58] The modification of KDIGO stage 1 AKI proposed by Marlies Ostermann et al introduced 3 substages (namely, 1S, 1A, and 1 B) and further categorized stages 2 and 3 AKI based on the presence of biomarkers in the JAMA Network Open. They proposed stage 1S.…”

Section: Timp-2 and Igfbp-7 For The Diagnosis In Csa-akimentioning

confidence: 99%

Mechanism and clinical role of TIMP-2 and IGFBP-7 in cardiac surgery-associated acute kidney injury: A review

Leng,

Li,

et al. 2024

Medicine

View full text Add to dashboard Cite

Acute kidney injury (AKI) is a common postoperative complication, but there is still a lack of accurate biomarkers. Cardiac surgery-associated AKI is the most common cause of major-surgery-related AKI, and patients requiring renal replacement therapy have high mortality rates. Early diagnosis, intervention, and management are crucial for improving patient prognosis. However, diagnosing AKI based solely on changes in serum creatinine level and urine output is insufficient, as these changes often lag behind actual kidney damage, making early detection challenging. Biomarkers such as tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein-7 (IGFBP-7) have been found to be significant predictors of moderate-to-severe AKI when combined with urine content analysis. This article reviews the mechanism of biomarkers TIMP-2 and IGFBP-7 in AKI and provides a comprehensive overview of the clinical effects of TIMP-2 and IGFBP-7 in cardiac surgery-associated AKI, including prediction, diagnosis, and progression.

show abstract

Section: Timp-2 and Igfbp-7 For The Diagnosis In Csa-akimentioning

confidence: 99%

Mechanism and clinical role of TIMP-2 and IGFBP-7 in cardiac surgery-associated acute kidney injury: A review

Leng,

Li,

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…Cardiac surgery with cardiopulmonary bypass, such as LVAD implantation, is a prototypical acute kidney injury-inducing insult. With increasing recognition of the importance of parenchymal kidney injury assessment, a study using a urine cell cycle arrest biomarker score [calculated by multiplication of the urine concentrations of insulin-like growth factor-binding protein 7 (IGFBP7), and tissue inhibitor of metalloproteinases-2 (TIMP-2)] found that elevated score 6 h after LVAD implantation was an independent predictor for development of moderate or severe AKI within 48 h of implantation; levels prior to LVAD implantation were not a predictor of this outcome [26 ▪▪ ]. An AKI prediction model for cardiac surgery was recently successfully developed and validated in large cohorts; however, it excluded LVAD recipients [27].…”

Section: Kidney Health and Left Ventricular Assist Devices: Durable M...mentioning

confidence: 99%

Kidney health and function with left ventricular assist devices

Garcia

Walther

2023

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

Purpose of reviewMechanical circulatory support (MCS) is a group of evolving therapies used for indications ranging from temporary support during a cardiac procedure to permanent treatment of advanced heart failure. MCS is primarily used to support left ventricle function, in which case the devices are termed left ventricular assist devices (LVADs). Kidney dysfunction is common in patients requiring these devices, yet the impact of MCS itself on kidney health in many settings remains uncertain.Recent findingsKidney dysfunction can manifest in many different forms in patients requiring MCS. It can be because of preexisting systemic disorders, acute illness, procedural complications, device complications, and long-term LVAD support. After durable LVAD implantation, most persons have improvement in kidney function; however, individuals can have markedly different kidney outcomes, and novel phenotypes of kidney outcomes have been identified.SummaryMCS is a rapidly evolving field. Kidney health and function before, during, and after MCS is relevant to outcomes from an epidemiologic perspective, yet the pathophysiology underlying this is uncertain. Improved understanding of the relationship between MCS use and kidney health is important to improving patient outcomes.

show abstract

Urinary Cell-Cycle Arrest Biomarkers as Early Predictors of Acute Kidney Injury After Ventricular Assist Device Implantation or Cardiac Transplantation

Cited by 2 publications

References 29 publications

Mechanism and clinical role of TIMP-2 and IGFBP-7 in cardiac surgery-associated acute kidney injury: A review

Mechanism and clinical role of TIMP-2 and IGFBP-7 in cardiac surgery-associated acute kidney injury: A review

Kidney health and function with left ventricular assist devices

Contact Info

Product

Resources

About